Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared with Warfarin among Long-term Anticoagulated Patients for Atrial Fibrillation

American Journal of Cardiology

Volumn 118, Issue 2, 2016, Pages 210-214

  Jacobs, Victoria ^a   May, Heidi T ^a   Bair, Tami L ^a   Crandall, Brian G ^a   Cutler, Michael J ^a   Day, John D ^a   Mallender, Charles ^a   Osborn, Jeffrey S ^a   Stevens, Scott M ^a   Weiss, J Peter ^a   Woller, Scott C ^a   Bunch, T Jared ^a  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ADVERSE OUTCOME; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COGNITION; CONTROLLED STUDY; DEATH; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAZARD RATIO; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SURVIVAL RATE; TRANSIENT ISCHEMIC ATTACK; VENOUS THROMBOEMBOLISM; VERY ELDERLY; COMPARATIVE STUDY; COMPLICATION; HEMORRHAGE; ISCHEMIC ATTACK, TRANSIENT; MORTALITY; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DEMENTIA; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; WARFARIN;

EID: 84969591027     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.04.039     Document Type: Article

References (19)

1. Z. Hijazi, S.H. Hohnloser, J. Oldgren, U. Andersson, S.J. Connolly, J.W. Eikelboom, M.D. Ezekowitz, P.A. Reilly, A. Siegbahn, S. Yusuf, and L. Wallentin Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis Circulation 129 2014 961 970
2. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, J.P. Piccini, R.C. Becker, C.C. Nessel, J.F. Paolini, S.D. Berkowitz, K.A. Fox, and R.M. Califf Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
3. G.J. Hankey, M.R. Patel, S.R. Stevens, R.C. Becker, G. Breithardt, A. Carolei, H.C. Diener, G.A. Donnan, J.L. Halperin, K.W. Mahaffey, J.L. Mas, A. Massaro, B. Norrving, C.C. Nessel, J.F. Paolini, R.O. Roine, D.E. Singer, L. Wong, R.M. Califf, K.A. Fox, and W. Hacke Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF Lancet Neurol 11 2012 315 322
4. M.R. Patel, A.S. Hellkamp, Y. Lokhnygina, J.P. Piccini, Z. Zhang, S. Mohanty, D.E. Singer, W. Hacke, G. Breithardt, J.L. Halperin, G.J. Hankey, R.C. Becker, C.C. Nessel, S.D. Berkowitz, R.M. Califf, K.A. Fox, and K.W. Mahaffey Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) J Am Coll Cardiol 61 2013 651 658
5. J.D. Easton, R.D. Lopes, M.C. Bahit, D.M. Wojdyla, C.B. Granger, L. Wallentin, M. Alings, S. Goto, B.S. Lewis, M. Rosenqvist, M. Hanna, P. Mohan, J.H. Alexander, and H.-C. Diener Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial Lancet Neurol 11 2012 503 511
6. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, H.R. Al-Khalidi, J. Ansell, D. Atar, A. Avezum, M.C. Bahit, R. Diaz, J.D. Easton, J.A. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B.J. Gersh, S. Golitsyn, S. Goto, A.G. Hermosillo, S.H. Hohnloser, J. Horowitz, P. Mohan, P. Jansky, B.S. Lewis, J.L. Lopez-Sendon, P. Pais, A. Parkhomenko, F.W. Verheugt, J. Zhu, L. Wallentin ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
7. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, and L. Wallentin Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
8. S.J. Connolly, J. Eikelboom, C. Joyner, H.C. Diener, R. Hart, S. Golitsyn, G. Flaker, A. Avezum, S.H. Hohnloser, R. Diaz, M. Talajic, J. Zhu, P. Pais, A. Budaj, A. Parkhomenko, P. Jansky, P. Commerford, R.S. Tan, K.H. Sim, B.S. Lewis, W. Van Mieghem, G.Y. Lip, J.H. Kim, F. Lanas-Zanetti, A. Gonzalez-Hermosillo, A.L. Dans, M. Munawar, M. O'Donnell, J. Lawrence, G. Lewis, R. Afzal, and S. Yusuf Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
9. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, A.L. Waldo, M.D. Ezekowitz, J.I. Weitz, J. Spinar, W. Ruzyllo, M. Ruda, Y. Koretsune, J. Betcher, M. Shi, L.T. Grip, S.P. Patel, I. Patel, J.J. Hanyok, M. Mercuri, E.M. Antman ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
10. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, P. Sinnaeve, A.J. Camm, and P. Kirchhof EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary Eur Heart J 34 2013 2094 2106
11. A. Kristiansen, L. Brandt, T. Agoritsas, E.A. Akl, E. Berge, A. Flem Jacobsen, L.P. Granan, S. Halvorsen, G. Guyatt, and P.O. Vandvik Applying new strategies for the national adaptation, updating, and dissemination of trustworthy guidelines: results from the Norwegian Adaptation of the Antithrombotic Therapy and the Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice guidelines Chest 146 2014 735 761
12. T.J. Bunch, J.P. Weiss, B.G. Crandall, H.T. May, T.L. Bair, J.S. Osborn, J.L. Anderson, J.B. Muhlestein, B.D. Horne, D.L. Lappe, and J.D. Day Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia Heart Rhythm 7 2010 433 437
13. C.S. Kwok, Y.K. Loke, R. Hale, J.F. Potter, and P.K. Myint Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis Neurology 76 2011 914 922
14. V. Jacobs, S.C. Woller, S. Stevens, H.T. May, T.L. Bair, J.L. Anderson, B.G. Crandall, J.D. Day, K. Johanning, Y. Long, C. Mallender, J.L. Olson, J.S. Osborn, J.P. Weiss, and T.J. Bunch Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia Heart Rhythm 11 2014 2206 2213
15. P. Santangeli, L. Di Biase, R. Bai, S. Mohanty, A. Pump, M. Cereceda Brantes, R. Horton, J.D. Burkhardt, D. Lakkireddy, Y.M. Reddy, M. Casella, A. Dello Russo, C. Tondo, and A. Natale Atrial fibrillation and the risk of incident dementia: a meta-analysis Heart Rhythm 9 2012 1761 1768
16. J.L. Anderson, B.D. Horne, S.M. Stevens, S.C. Woller, K.M. Samuelson, J.W. Mansfield, M. Robinson, S. Barton, K. Brunisholz, C.P. Mower, J.A. Huntinghouse, J.S. Rollo, D. Siler, T.L. Bair, S. Knight, J.B. Muhlestein, and J.F. Carlquist A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II) Circulation 125 2012 1997 2005
17. P.S. Christensen, S. Towner, S.M. Stevens, D. Hale, and S.C. Woller Anti-tampering for mildly out of range international normalized ratio values in chronically anticoagulated patients Exp Clin Cardiol 20 2014 5970 5985
18. C.T. Ruff, R.P. Giugliano, E. Braunwald, E.B. Hoffman, N. Deenadayalu, M.D. Ezekowitz, A.J. Camm, J.I. Weitz, B.S. Lewis, A. Parkhomenko, T. Yamashita, and E.M. Antman Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials Lancet 383 2014 955 962
19. Jacobs V, Woller SC, Stevens SM, May HT, Bair TL, Crandall BG, Cutler M, Day JD, Weiss JP, Osborn JS, Mallender C, Anderson JL, Bunch TJ. Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. J Cardiovasc Electrophysiol. 2015. Epub 2015/08/14. http://dx.doi.org/10.1111/jce.12776.